Semaglutide shows promise in reducing alcohol cravings and consumption. Could it be a future treatment for AUD?

(HealthDay News) — Low-dose semaglutide seems to reduce craving and certain drinking outcomes in alcohol use disorder (AUD), according to a study published online Feb. 12 in JAMA Psychiatry.

Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.

NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients ...

The researchers found that low-dose semaglutide (0.25 mg/week for 4 weeks, 0.5 mg/week for 4 weeks, and 1 mg for one week) reduced the amount of alcohol consumed during a posttreatment laboratory ...